Physician profile
Lauren Schwartz
NPI 1033389689
$129,420.93
in general payments reported to CMS, 2019-2025
29 companies · $22K in 2025
The $22K reported for 2025 was more than what 95% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,951 · 2020: $21K · 2021: $14K · 2022: $25K · 2023: $22K · 2024: $17K · 2025: $22K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $37K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $13K · Food and Beverage: $5,969 · Travel and Lodging: $4,403.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $37,300.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $13,257.00 |
| Food and Beverage | $5,969.40 |
| Travel and Lodging | $4,403.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $61,715.07 | 2020-2025 | Gattex, Entyvio |
| E.R. Squibb & Sons, L.L.C. | $47,522.40 | 2021-2024 | Zeposia |
| Shire North American Group INC | $7,519.70 | 2019 | |
| Celgene Corporation | $5,795.79 | 2021-2024 | Zeposia |
| Abbvie INC. | $3,065.12 | 2020-2025 | Skyrizi, Rinvoq, Viberzi |
| Janssen Biotech, INC. | $1,408.88 | 2019-2025 | Tremfya, Stelara |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $464.46 | 2020-2025 | Xifaxan, Trulance |
| Pfizer INC. | $371.04 | 2020-2025 | |
| Qol Medical, LLC | $286.96 | 2019-2025 | Sucraid, Sucraid |
| Celltrion USA INC. | $235.87 | 2025 | Vegzelma |
| Ironwood Pharmaceuticals, INC | $150.18 | 2019-2024 | Linzess |
| Ardelyx, INC. | $136.68 | 2024-2025 | Ibsrela |
| Ethicon US, LLC | $124.99 | 2019 | |
| Madrigal Pharmaceuticals | $108.43 | 2024-2025 | Resmetirom, Rezdiffra |
| Allergan, INC. | $60.07 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $58.69 | 2023-2024 | Accrufer |
| Gilead Sciences, INC. | $55.14 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $47.73 | 2023 | Dupixent |
| Nestle Healthcare Nutrition INC. | $45.14 | 2021 | |
| Braintree Laboratories, INC. | $35.86 | 2023 | Suflave, Sutab |
| Aimmune Therapeutics, INC. | $35.72 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.84 | 2023 | Cyltezo |
| Incyte Corporation | $27.29 | 2023 | Opzelura |
| Vibrant Gastro, INC. | $24.70 | 2025 | Vibrant Starter Kit |
| Galderma Laboratories, L.P. | $24.00 | 2024 | |
| Phathom Pharmaceuticals, INC. | $20.50 | 2025 | Voquezna |
| Ipsen Biopharmaceuticals, INC | $20.08 | 2025 | Iqirvo |
| Redhill Biopharma INC. | $14.56 | 2021 | |
| 180 Medical, INC. | $12.04 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lauren Schwartz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.